ArticleAmerican journal of preventive cardiology2025
Relationship between interleukin-6, coronary artery calcium and risk of heart failure: Insights from MESA.
Article in American journal of preventive cardiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: This study investigated the joint association of interleukin-6 (IL-6) and coronary artery calcium (CAC) with the risk of heart failure (HF). Methods and Results: Among 6592 participants in the Multi-Ethnic Study of Atherosclerosis (MESA), individuals were categorized into four groups based on CAC (0 vs >0) and IL-6 (cutoff 1.32 pg/mL via Youden's index): low CAC/low IL-6 (reference), low CAC/high IL-6, high CAC/low IL-6, and high CAC/high IL-6. Multivariable Cox models were used to assess the risk of total heart failure (HF), HF with reduced ejection fraction (HFrEF), and HF with preserved ejection fraction (HFpEF). Compared to the reference group, the hazard ratios (HRs) for total HF were 1.61 (95 % CI, 1.12-2.31) for high IL-6, 1.56 (95 % CI, 1.11-2.20) for high CAC, and 2.00 (95 % CI, 1.43-2.80) when both were elevated (multiplicative interaction Conclusions: Combined elevation of IL-6 and CAC was associated with increased HFrEF risk, with significant additive and multiplicative interactions. For HFpEF, combined elevation conferred less risk than either alone. Inflammation modifies the CAC-HFrEF relationship and merits further study.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.